<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04379219</url>
  </required_header>
  <id_info>
    <org_study_id>R.19.10.639.R1.R2.R3</org_study_id>
    <nct_id>NCT04379219</nct_id>
  </id_info>
  <brief_title>Surgery Alone Versus Methotrexate Before Surgery in Cesarean Scar Pregnancy</brief_title>
  <official_title>Surgery Alone Versus Methotrexate Before Surgery in Cases of First Trimester Cesarean Scar Pregnancy: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are no universal treatment guidelines available. The ultimate purpose of the management
      of CSP is to simultaneously remove the pregnancy and successfully preserve the woman's
      fertility (Gonzalez &amp; Tulandi, 2017). A variety of medical and surgical treatment modalities
      for CSP have been reported; however, most of these are based on low‐level evidence(Sun et
      al., 2019).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized clinical trial to evaluate the effect of administration of
      methotrexate before surgery in reducing bleeding, injury to bladder and ureter, operative
      time and removing of CSP mass.This will be in comparison to surgery alone in cases of first
      trimester cesarean scar pregnancy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated blood loss intraoperative</measure>
    <time_frame>intraoperative blood loss</time_frame>
    <description>the amount of blood in soaked towels and vacuum aspiration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>need further management</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Rate of urological injury</measure>
    <time_frame>immediatly and 1 week post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Rate of readmission, relaparotomy</measure>
    <time_frame>with in 1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Cesarean Scar Pregnancy</condition>
  <arm_group>
    <arm_group_label>surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valid consent
Anathesia , (regional may br converted into general ). IV antibiotic ( cefotaxime 1 gm I.V )
Laparotomy transverse incision (pfannenstiel incision)
Exploration of the abdominal cavity
Identification of the uterus, dissection of the bladder, incision of the uterus and excision of the CSP mass.
Surgical repair of the uterine incision, and the abdomen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methotrexate before surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valid consent
patient will receive 50 mgm /m2 of methtrexate after full investigation ( CBC, serum creatinie, AlT, AST), 1 week before surgery.
Anathesia , (regional may br converted into general ). IV antibiotic ( cefotaxime 1 gm I.V )
Laparotomy transverse incision (pfannenstiel incision)
Exploration of the abdominal cavity
Identification of the uterus, dissection of the bladder, incision of the uterus and excision of the CSP mass.
Surgical repair of the uterine incision, and the abdomen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>giving methotrexate at least 1 w week before surgery</description>
    <arm_group_label>methotrexate before surgery</arm_group_label>
    <arm_group_label>surgery</arm_group_label>
    <other_name>unitrexate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:•

          -  Gestational age before 13 w

          -  Past history of 1 or more CS

          -  Presence of GS implanted on cesareans scar

        Exclusion Criteria:

          -  Presence of severe vaginal bleeding (emergency)

          -  Previous history of uterine surgery other than CS

          -  The whole mass is interior and the bulge is more in the cavity

          -  Bleeding disorder

          -  Patient not candidate for methotrexate (Positive fetal heart pulsation,

          -  Patient refuse to participate in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maher Elgaly</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maher Elesawi Elgaly, M.D MRCOG</last_name>
    <phone>+2 01016406182</phone>
    <email>mahereleswi@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mansoura University</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahliya</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maher Elgaly, MD,MRCOG</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Maher elesawi kamel elesawi</investigator_full_name>
    <investigator_title>Lecturer of obstetric and gynecology</investigator_title>
  </responsible_party>
  <keyword>cesarean scar pregnancy, methotrexate, miscarriage, ectopic pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

